MA33127B1 - Composition liposomique - Google Patents

Composition liposomique

Info

Publication number
MA33127B1
MA33127B1 MA34174A MA34174A MA33127B1 MA 33127 B1 MA33127 B1 MA 33127B1 MA 34174 A MA34174 A MA 34174A MA 34174 A MA34174 A MA 34174A MA 33127 B1 MA33127 B1 MA 33127B1
Authority
MA
Morocco
Prior art keywords
liposomes
combination
relates
liposomal composition
eribuline
Prior art date
Application number
MA34174A
Other languages
Arabic (ar)
English (en)
Inventor
Hiroshi Kikuchi
Kenji Hyodo
Hiroshi Ishihara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33127(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA33127B1 publication Critical patent/MA33127B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE COMPOSITION LIPOSOMIQUE QUI CONTIENT DE L'ERIBULINE OU UN SEL DE QUALITÉ PHARMACEUTIQUE DE CELUI-CI. L'INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ DE MISE AU POINT DE CETTE COMPOSITION LIPOSOMIQUE.
MA34174A 2009-03-30 2010-03-30 Composition liposomique MA33127B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
JP2009082521 2009-03-30
PCT/JP2010/055770 WO2010113984A1 (fr) 2009-03-30 2010-03-30 Composition liposomique

Publications (1)

Publication Number Publication Date
MA33127B1 true MA33127B1 (fr) 2012-03-01

Family

ID=42828273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34174A MA33127B1 (fr) 2009-03-30 2010-03-30 Composition liposomique

Country Status (33)

Country Link
US (3) US20120058178A1 (fr)
EP (1) EP2415470B1 (fr)
JP (1) JP5551683B2 (fr)
KR (1) KR101495951B1 (fr)
CN (1) CN102369008B (fr)
AU (1) AU2010232347A1 (fr)
BR (1) BRPI1014527B8 (fr)
CA (1) CA2756811C (fr)
CO (1) CO6430500A2 (fr)
CY (1) CY1118231T1 (fr)
DK (1) DK2415470T3 (fr)
ES (1) ES2593027T3 (fr)
HK (1) HK1165707A1 (fr)
HR (1) HRP20161157T1 (fr)
HU (1) HUE029577T2 (fr)
IL (1) IL215059A (fr)
LT (1) LT2415470T (fr)
MA (1) MA33127B1 (fr)
ME (1) ME02518B (fr)
MX (1) MX2011009632A (fr)
MY (1) MY160203A (fr)
NZ (1) NZ595212A (fr)
PE (2) PE20120923A1 (fr)
PL (1) PL2415470T3 (fr)
PT (1) PT2415470T (fr)
RS (1) RS55148B1 (fr)
SG (1) SG174255A1 (fr)
SI (1) SI2415470T1 (fr)
SM (1) SMT201600307B (fr)
TW (1) TWI392519B (fr)
UA (1) UA103794C2 (fr)
WO (1) WO2010113984A1 (fr)
ZA (1) ZA201106535B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
EP2680839A1 (fr) 2011-03-02 2014-01-08 Morphotek, Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
KR102554628B1 (ko) 2013-02-01 2023-07-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
EP3177269A4 (fr) 2014-08-04 2018-02-28 Zoneone Pharma, Inc. Chargement à distance de médicaments modérément hydrosolubles dans des vésicules lipidiques
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
ES2898844T3 (es) 2015-09-18 2022-03-09 Univ Muenchen Tech Ligandos para integrina alphavbeta6, síntesis y usos de los mismos
WO2017078009A1 (fr) * 2015-11-02 2017-05-11 富士フイルム株式会社 Composition liposomale et son procédé de production
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
IL268099B2 (en) 2017-01-18 2024-05-01 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes that increase targeting of mitotic cells
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
AU2018246024B2 (en) * 2017-03-31 2020-08-06 Fujifilm Corporation Liposome composition and pharmaceutical composition
EP3713565A1 (fr) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Associations pharmaceutiques destinées à être utilisées dans le traitement du cancer
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
TW202143955A (zh) 2020-05-29 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 含有乙二胺四乙酸或其鹽的艾日布林或其可藥用鹽脂質體
CN115957351B (zh) * 2022-11-15 2023-06-27 中国人民解放军海军第九七一医院 一种碘海醇注射液及其制备方法
WO2024199424A1 (fr) * 2023-03-30 2024-10-03 上海济煜医药科技有限公司 Composition de phospholipide, son procédé de préparation et utilisation d'un composé contenant de l'azote

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
ES2188612T3 (es) 1993-04-22 2003-07-01 Skyepharma Inc Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
WO1999065894A1 (fr) 1998-06-17 1999-12-23 Eisai Co., Ltd. Analogues macrocycliques, leurs procedes d'utilisation et de preparation
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
EP1448165B1 (fr) 2001-11-13 2007-09-19 Celator Pharmaceuticals, Inc. Compositions a vecteurs lipidiques et procedes garantissant une meilleure retention medicamenteuse
AU2002340669A1 (en) 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
KR101133084B1 (ko) 2002-12-31 2012-04-04 자이더스 비에스브이 파마 프라이빗 리미티드 장기간 순환성 비-페길레이티드 리포좀
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20070112176A1 (en) * 2003-04-04 2007-05-17 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structure containing anti-mt-mmp monoclonal antibody
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2553573A1 (fr) 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. Methode de stabilisation d'un compose de macrolide
KR101462819B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
EP1750673B1 (fr) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Formulations liposomales comprenant de la dihydrosphingomyéline, et procedés d'utilisation correspondants
USRE46965E1 (en) 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
CA2582949A1 (fr) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes permettant une meilleure retention du medicament, destines au traitement du cancer
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20090196913A1 (en) 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US20090196918A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
CN102245640B (zh) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
RU2476216C1 (ru) 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
RU2405601C1 (ru) 2009-05-19 2010-12-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения злокачественных опухолей мочевого пузыря
JP5388735B2 (ja) 2009-07-21 2014-01-15 浜松ホトニクス株式会社 マイクロチャンネルプレート
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
EP2680839A1 (fr) 2011-03-02 2014-01-08 Morphotek, Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
SG10201602147YA (en) 2011-03-18 2016-05-30 Eisai R&D Man Co Ltd Methods And Compositions For Predicting Response To Eribulin
TR201810298T4 (tr) 2011-03-31 2018-08-27 Merck Sharp & Dohme İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
EP2693875A4 (fr) 2011-04-08 2014-10-22 British Columbia Cancer Agency Composés de bisphénol et leurs procédés d'utilisation
US9532949B2 (en) 2011-07-19 2017-01-03 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
CA2892780A1 (fr) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Utilisation d'eribuline dans le traitement de cancer du sein
EP2970473B1 (fr) 2013-03-14 2017-08-16 Bristol-Myers Squibb Company Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
WO2014193898A1 (fr) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Thérapies combinées contre le cancer
CA2912346A1 (fr) 2013-06-11 2014-12-18 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de pi3k et d'un destabilisateur de microtubule
EP3013335B1 (fr) 2013-06-26 2018-11-07 Eisai R&D Management Co., Ltd. Polythérapie destinée au traitement du cancer contenant d'éribuline et du lenvatinib
EP3046543A1 (fr) 2013-09-18 2016-07-27 Stc.Unm Nanoparticules de silice mésoporeuse toroïdales (tmsnp) et proto-cellules associées
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
WO2015095784A1 (fr) 2013-12-19 2015-06-25 Luminus Biosciences, Inc. Formulation de nanoparticules solides d'inhibiteurs des microtubules à mûrissement d'ostwald réduit pour une administration par voie orale
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3113775A4 (fr) 2014-03-03 2017-08-23 Eisai R&D Management Co., Ltd. Utilisation d'éribuline et d'inhibiteurs de mtor en tant que polythérapie pour le traitement du cancer
WO2015134605A1 (fr) 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
WO2015184145A1 (fr) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Utilisation de l'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer
WO2015183961A1 (fr) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Utilisation de l'éribuline dans le traitement du cancer
MA40921A (fr) 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物
JP2016133331A (ja) 2015-01-16 2016-07-25 ソニー株式会社 電気的測定用カートリッジ、生体試料用電気的測定装置及び生体試料用電気的測定方法
RU2723021C2 (ru) 2015-02-12 2020-06-08 Бейондспринг Фармасьютикалс, Инк. Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа
BR112017018872A2 (pt) 2015-03-04 2018-05-29 Eisai R&D Man Co Ltd combinação de um antagonista pd-1 e eribulina para tratamento de câncer
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
US20190263927A1 (en) 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Also Published As

Publication number Publication date
UA103794C2 (en) 2013-11-25
MX2011009632A (es) 2011-10-19
DK2415470T3 (en) 2016-09-19
US11071713B2 (en) 2021-07-27
CN102369008A (zh) 2012-03-07
IL215059A0 (en) 2011-11-30
BRPI1014527B1 (pt) 2020-11-24
CO6430500A2 (es) 2012-04-30
TWI392519B (zh) 2013-04-11
HK1165707A1 (zh) 2012-10-12
CY1118231T1 (el) 2017-06-28
US12042560B2 (en) 2024-07-23
ME02518B (fr) 2017-02-20
JPWO2010113984A1 (ja) 2012-10-11
RS55148B1 (sr) 2016-12-30
CA2756811A1 (fr) 2010-10-07
JP5551683B2 (ja) 2014-07-16
US20120058178A1 (en) 2012-03-08
KR20110122219A (ko) 2011-11-09
US20210023004A1 (en) 2021-01-28
NZ595212A (en) 2014-02-28
IL215059A (en) 2016-03-31
HUE029577T2 (en) 2017-03-28
BRPI1014527A2 (pt) 2016-04-05
PE20151519A1 (es) 2015-10-28
BRPI1014527B8 (pt) 2021-05-25
PE20120923A1 (es) 2012-08-27
SI2415470T1 (sl) 2016-12-30
AU2010232347A1 (en) 2011-09-29
PL2415470T3 (pl) 2016-12-30
HRP20161157T1 (hr) 2016-11-18
SMT201600307B (it) 2016-11-10
PT2415470T (pt) 2016-08-31
EP2415470A4 (fr) 2012-11-28
EP2415470B1 (fr) 2016-07-06
KR101495951B1 (ko) 2015-02-25
CN102369008B (zh) 2014-10-29
CA2756811C (fr) 2014-09-23
TW201102110A (en) 2011-01-16
ES2593027T3 (es) 2016-12-05
EP2415470A1 (fr) 2012-02-08
SG174255A1 (en) 2011-10-28
ZA201106535B (en) 2012-05-30
US20140044777A1 (en) 2014-02-13
MY160203A (en) 2017-02-28
LT2415470T (lt) 2016-10-10
WO2010113984A1 (fr) 2010-10-07

Similar Documents

Publication Publication Date Title
MA33127B1 (fr) Composition liposomique
MA37379A1 (fr) Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
MA33826B1 (fr) Analogue du peptide d'oxyntomoduline
MA35359B1 (fr) Lutte biologique contre les nématodes
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
PT1913001E (pt) (r)-n-metilnaltrexona, processos para a sua síntese e sua utilização farmacêutica
WO2010048477A3 (fr) Procede ameliore de preparation de produits couples a partir de 4-amino-3-cyanoquinoleines utilisant des intermediaires stabilises
EP2940017A3 (fr) Processus de préparation de composés utiles en tant qu'inhibiteurs de kinase d'ATR
NO20076371L (no) Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
MA55193B1 (fr) Procédés de préparation d'un inhibiteur de pi3k
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
MX2007005936A (es) Una sintesis asimetrica del acido (s)-(+)-3-(aminometil)-5- metilhexanoico.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
MX2011011272A (es) Procesos e intermediarios.
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX2008012424A (es) Proceso convergente para la sintesis de derivados de taxanos.
EA201390156A1 (ru) ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
MA31603B1 (fr) Nouvelle forme cristalline du 3-(difluorométhyle)-1-méthyle-n-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1h-pyrazole-4-carboxamide
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов